Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15595698 | 0.94 | MAPT (0.60) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL31238673 | 0.94 | SMPD1 (0.54) | MAPTPRSS1SMPD1MGLLHDAC6 | |
| SCHEMBL5767014 | 0.94 | MAPT (0.64) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL15574247 | 0.90 | MAPT (0.62) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL2149738 | 0.90 | MAPT (0.66) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL29171438 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL29171419 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL29171445 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL14930509 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL29171407 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289659-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-10624972-B2 | Conjugates for treating diseases | ENDOCYTE, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| WO-2016148674-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624972-B2 | Conjugates for treating diseases | CD79B, MALT1, TPMT | MAPT 1077/4885PRSS1 3103/4885SMPD1 64/4885 |
| US-20200289659-A1 | CONJUGATES FOR TREATING DISEASES | CD79B, MALT1, TPMT | MAPT 1077/4885PRSS1 3103/4885SMPD1 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.